{"disease":{"id":"splenomegaly","name":"Splenomegaly","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"ruxolitinib","indication_name":"Splenomegaly","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Jakafi","generic_name":"RUXOLITINIB","company_name":"Incyte Corp","drug_phase":"marketed","molecular_target":"Ankyrin repeat and protein kinase domain-containing protein 1, Bone morphogenetic protein receptor type-1B, Calcium/calmodulin-dependent protein kinase type IV","drug_class":"","quality_score":null,"revenue":"2600","mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05641103","title":"PREDIGA 2: Spanish Acronym of \"Educational and Diagnostic Project for Gaucher and ASMD\"","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Fundación Española de Hematología y Hemoterapía","has_results":false},{"nct_id":"NCT02871219","title":"Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT04716166","title":"Incentive Spirometry and Upper Abdominal Laparoscopic Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Riphah International University","has_results":false},{"nct_id":"NCT04845958","title":"A Non-Interventional National Study in Pediatric Patients With Unexplained Enlarged Spleen","phase":"","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06909136","title":"A Study to Evaluate Safety , Efficacy and Pharmacokinetics of WJ01024 Tablets Combined With Ruxolitinib in Patients With Myelofibrosis","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Suzhou Junjing BioSciences Co., Ltd.","has_results":false},{"nct_id":"NCT06345495","title":"High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05050994","title":"Ultrasound Guided Microwave Ablation of Splenomegaly in Children","phase":"NA","overall_status":"UNKNOWN","enrollment_count":10,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT03801434","title":"Ruxolitinib in Treating Patients With Hypereosinophilic Syndrome or Primary Eosinophilic Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"William Shomali","has_results":false},{"nct_id":"NCT02421354","title":"Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02730884","title":"Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":3,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02948283","title":"Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT01457443","title":"Biomarker for Pompe Disease (BioPompe)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT02298647","title":"Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT01331642","title":"Biomarker for Gaucher Disease: BioGaucher (BioGaucher)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT02298699","title":"Biomarker for Sly Disease (MPS VII) (BioSly)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT02298634","title":"Biomarker for Farber Disease (BioFarber)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}